First National Advisers LLC Sells 5,685 Shares of Revvity, Inc. (NYSE:RVTY)

First National Advisers LLC trimmed its position in Revvity, Inc. (NYSE:RVTY) by 35.7% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 10,238 shares of the company’s stock after selling 5,685 shares during the period. First National Advisers LLC’s holdings in Revvity were worth $1,143,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of the company. Gladius Capital Management LP acquired a new position in shares of Revvity in the 3rd quarter valued at $32,000. Assetmark Inc. lifted its stake in shares of Revvity by 3,700.0% in the 4th quarter. Assetmark Inc. now owns 266 shares of the company’s stock valued at $30,000 after purchasing an additional 259 shares during the period. Continuum Advisory LLC lifted its stake in shares of Revvity by 2,972.7% in the 3rd quarter. Continuum Advisory LLC now owns 338 shares of the company’s stock valued at $43,000 after purchasing an additional 327 shares during the period. MassMutual Private Wealth & Trust FSB lifted its stake in shares of Revvity by 55.9% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 385 shares of the company’s stock valued at $43,000 after purchasing an additional 138 shares during the period. Finally, Avior Wealth Management LLC lifted its stake in shares of Revvity by 7,980.0% in the 3rd quarter. Avior Wealth Management LLC now owns 404 shares of the company’s stock valued at $52,000 after purchasing an additional 399 shares during the period. 86.65% of the stock is currently owned by institutional investors.

Insider Activity

In other news, insider Tajinder S. Vohra sold 5,492 shares of the firm’s stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $116.81, for a total value of $641,520.52. Following the completion of the transaction, the insider now owns 19,652 shares in the company, valued at $2,295,550.12. This trade represents a 21.84 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Joel S. Goldberg sold 15,170 shares of Revvity stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $126.73, for a total value of $1,922,494.10. Following the transaction, the insider now owns 33,400 shares of the company’s stock, valued at $4,232,782. The trade was a 31.23 % decrease in their position. The disclosure for this sale can be found here. 0.60% of the stock is owned by corporate insiders.

Revvity Stock Performance

RVTY opened at $112.13 on Monday. The business’s 50-day moving average price is $117.01 and its two-hundred day moving average price is $117.93. Revvity, Inc. has a 1 year low of $97.32 and a 1 year high of $129.50. The company has a market capitalization of $13.47 billion, a price-to-earnings ratio of 50.74, a P/E/G ratio of 3.82 and a beta of 1.06. The company has a debt-to-equity ratio of 0.41, a current ratio of 3.60 and a quick ratio of 3.03.

Revvity (NYSE:RVTY) last announced its quarterly earnings data on Friday, January 31st. The company reported $1.42 earnings per share for the quarter, beating the consensus estimate of $1.37 by $0.05. Revvity had a return on equity of 7.68% and a net margin of 9.81%. During the same period in the previous year, the business posted $1.25 earnings per share. Equities analysts expect that Revvity, Inc. will post 4.94 EPS for the current fiscal year.

Revvity Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 9th. Stockholders of record on Friday, April 18th will be issued a $0.07 dividend. This represents a $0.28 annualized dividend and a dividend yield of 0.25%. The ex-dividend date of this dividend is Thursday, April 17th. Revvity’s payout ratio is 12.67%.

Analyst Upgrades and Downgrades

RVTY has been the topic of several research analyst reports. Raymond James reaffirmed an “outperform” rating and set a $145.00 price objective (up previously from $140.00) on shares of Revvity in a research note on Monday, February 3rd. Barclays raised their price objective on Revvity from $135.00 to $140.00 and gave the stock an “overweight” rating in a research note on Monday, February 3rd. KeyCorp raised their price objective on Revvity from $132.00 to $145.00 and gave the stock an “overweight” rating in a research note on Monday, February 3rd. Sanford C. Bernstein downgraded Revvity from an “outperform” rating to a “market perform” rating and set a $130.00 price objective on the stock. in a research note on Friday, January 10th. Finally, Bank of America raised Revvity from a “neutral” rating to a “buy” rating and set a $138.00 price objective on the stock in a research note on Friday, December 13th. Four research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Revvity presently has an average rating of “Moderate Buy” and a consensus price target of $136.25.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.